An open-label study of the effect of Bondronat [ibandronic acid] on bone pain in patients with prostate cancer and bone metastases experiencing moderate to severe pain

Trial Profile

An open-label study of the effect of Bondronat [ibandronic acid] on bone pain in patients with prostate cancer and bone metastases experiencing moderate to severe pain

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 18 Nov 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 23 Jan 2008 Status changed from recruiting to in progress.
    • 18 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top